SALL4 and cancer: This study, which included a larger series of 1,815 patients, reported that 16.7% of GC tumors were SALL4-positive and that SALL4 positivity was associated with cancer progression-related clinicopathologic parameters, such as advanced stage, lymph node metastasis, and vascular invasion.